{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:55:37Z","timestamp":1791705337991,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.pupt.2023.102264","type":"journal-article","created":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T05:20:58Z","timestamp":1698556858000},"page":"102264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Medication use in people with cystic fibrosis before and after modulator therapy"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8436-0932","authenticated-orcid":false,"given":"Louise","family":"Lord","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam TY.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedidiah I.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni","family":"Ilomaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10059","key":"10.1016\/j.pupt.2023.102264_bib1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pupt.2023.102264_bib2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2023.102264_bib3","series-title":"Australian Cystic Fibrosis Data Registry 2021","article-title":"The Australian cystic fibrosis data registry annual report 2021","author":"Ahern","year":"2021"},{"issue":"2","key":"10.1016\/j.pupt.2023.102264_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J. Cyst. Fibros."},{"issue":"7","key":"10.1016\/j.pupt.2023.102264_bib5","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1 Suppl","key":"10.1016\/j.pupt.2023.102264_bib6","doi-asserted-by":"crossref","first-page":"1s","DOI":"10.1378\/chest.125.1_suppl.1S","article-title":"Cystic fibrosis adult care: consensus conference report","volume":"125","author":"Yankaskas","year":"2004","journal-title":"Chest"},{"issue":"6 Suppl","key":"10.1016\/j.pupt.2023.102264_bib7","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jpeds.2009.09.001","article-title":"Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis","volume":"155","author":"Borowitz","year":"2009","journal-title":"J. Pediatr."},{"issue":"4","key":"10.1016\/j.pupt.2023.102264_bib8","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-1784","article-title":"Clinical practice guidelines from the cystic fibrosis foundation for preschoolers with cystic fibrosis","volume":"137","author":"Lahiri","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.pupt.2023.102264_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.pupt.2023.102264_bib10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.12.009","article-title":"Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes","volume":"12","author":"Sawicki","year":"2013","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.pupt.2023.102264_bib11","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/thoraxjnl-2017-210473","article-title":"The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers","volume":"73","author":"Rowbotham","year":"2018","journal-title":"Thorax"},{"issue":"155","key":"10.1016\/j.pupt.2023.102264_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0051-2020","article-title":"Modulator treatment for people with cystic fibrosis: moving in the right direction","volume":"29","author":"Elborn","year":"2020","journal-title":"Eur. Respir. Rev."},{"issue":"2","key":"10.1016\/j.pupt.2023.102264_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1513\/AnnalsATS.201909-671CME","article-title":"The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis","volume":"17","author":"Sergeev","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.pupt.2023.102264_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107845","article-title":"Effect of CFTR modulator therapy on cystic fibrosis-related diabetes","volume":"35","author":"Gaines","year":"2021","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.pupt.2023.102264_bib15","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S1569-1993(20)30528-2","article-title":"Impact of ivacaftor on polypharmacy in adults with cystic fibrosis","volume":"19","author":"Dooney","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2023.102264_bib16","article-title":"Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy","author":"Gifford","year":"2019","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.pupt.2023.102264_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2023.102264_bib18","article-title":"Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials","author":"Keogh","year":"2021","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.pupt.2023.102264_bib19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jcf.2021.08.014","article-title":"Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?","volume":"21","author":"Granger","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.pupt.2023.102264_bib20","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jcf.2021.03.008","article-title":"Real-world use of ivacaftor in Canada: a retrospective analysis using the Canadian Cystic Fibrosis Registry","volume":"20","author":"Kawala","year":"2021","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.pupt.2023.102264_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2023.102264_bib22","series-title":"Commonwealth of Australia","article-title":"About the PBS","author":"Australian Government Department of Health","year":"2023"},{"key":"10.1016\/j.pupt.2023.102264_bib23","article-title":"Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials","author":"Davies","year":"2019","journal-title":"J. Cyst. Fibros."},{"issue":"12","key":"10.1016\/j.pupt.2023.102264_bib24","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1080\/09593985.2019.1709591","article-title":"Pediatric hospital in the home: clinical outcomes for treatment of a cystic fibrosis respiratory exacerbation","volume":"37","author":"Hough","year":"2021","journal-title":"Physiother. Theory Pract."},{"issue":"1","key":"10.1016\/j.pupt.2023.102264_bib25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s41030-021-00154-9","article-title":"Long-term impact of ivacaftor on healthcare resource utilization among people with cystic fibrosis in the United States","volume":"7","author":"Thorat","year":"2021","journal-title":"Pulm Ther"},{"issue":"2","key":"10.1016\/j.pupt.2023.102264_bib26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/1479972316631135","article-title":"Pain and its clinical associations in individuals with cystic fibrosis: a systematic review","volume":"13","author":"Lee","year":"2016","journal-title":"Chron. Respir. Dis."},{"issue":"1","key":"10.1016\/j.pupt.2023.102264_bib27","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.jcf.2021.06.007","article-title":"Satisfaction and effectiveness of opioid pain management among adults with cystic fibrosis: a mixed methods study","volume":"21","author":"Allgood","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.pupt.2023.102264_bib28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00127-022-02307-w","article-title":"Depression and anxiety prevalence in people with cystic fibrosis and their caregivers: a systematic review and meta-analysis","volume":"58","author":"Lord","year":"2023","journal-title":"Soc. Psychiatr. Psychiatr. Epidemiol."},{"issue":"6","key":"10.1016\/j.pupt.2023.102264_bib29","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2023.102264_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221144211","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on depression and anxiety in cystic fibrosis","volume":"16","author":"Zhang","year":"2022","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"5","key":"10.1016\/j.pupt.2023.102264_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11050418","article-title":"Fertility, pregnancy and lactation considerations for women with CF in the CFTR modulator era","volume":"11","author":"Jain","year":"2021","journal-title":"J. Personalized Med."},{"issue":"6","key":"10.1016\/j.pupt.2023.102264_bib32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jcf.2020.07.022","article-title":"The impact of the COVID-19 pandemic on the emotional well-being and home treatment of Belgian patients with cystic fibrosis, including transplanted patients and paediatric patients","volume":"19","author":"Havermans","year":"2020","journal-title":"J. Cyst. Fibros. : official journal of the European Cystic Fibrosis Society"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:32:25Z","timestamp":1761082345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553923000767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":32,"alternative-id":["S1094553923000767"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102264","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication use in people with cystic fibrosis before and after modulator therapy","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102264"}}